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The design and development of in vivo glucose
sensors for an artificial endocrine pancreas
GILBERTOD. VELHO, GERARD REACH, and
DANIEL R. THÉVENOT
22.1 Introduction
Insulin, a polypeptide hormone produced by the beta-cells of the pancreas, is
essential in many metabolic pathways for carbohydrates, proteins, and fats;
in the absence of normal insulin secretion, body fuel homeostasis is
deranged. Diabetes mellitus is characterized by a relative or an absolute
insulin deficiency manifested by loss of control of the circulating blood
glucose levels, and by other metabolic abnormalities.
Diabetes is a common disease in affluent societies, affecting from one to
three per cent of the population, and often five to ten per cent of those over 40
years of age (Hamman 1983). Where systematic surveys have been performed
in the developing nations, rates of one to two per cent of the total population
prevail (Bennett 1983). Thus, diabetes is a major worldwide health problem
with a great social and economic impact due largely to its later complications.
Albisser and Spencer (1982) referring to the Report of the National Com¬
mission on Diabetes to the Congress of the United States (1976) suggest that,
in that country, diabetics are 25 times more prone to blindness than
non-diabetics, 17 times more prone to kidney disease, 5 times more prone to
gangrene, twice as prone to heart disease, and have a life expectancy of
approximately one-third less than the general population.
Diabetes mellitus is an heterogeneous disease and only a minority of
patients, representing however 3 per 1000 of the general population, are so
severely insulinopenic as to require insulin therapy. Since its introduction in
the early twenties up to the last years of the seventies, insulin therapy was
possible only through discontinuous insulin administration, by one, two, or
occasionally, several daily insulin injections.
The search for better methods for treating insulin-dependent diabetes and
its complications has led to the development of new devices for insulin
therapy in the last decade. Infusion systems for continuous insulin delivery
(insulin pump), including a reservoir, a pump, and a power supply packed
into a portable single unit, have been made available to clinicians and diabetic
patients. Efforts to develop a portable self-regulated system, associating an
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Fig. 22.1 Scheme of three possible methods of insulin therapy.
(a) Intensive conventional therapy: multiple insulin injections dependent on manual
glucose measurement with reacting strips.
(b) Open-loop system: continuous preprogrammed insulin infusion dependent on
manual glucose measurement with reacting strips.
(c) Closed-loop system: continuous self-regulated insulin infusion. The glucose level,
continuously measured by the sensor, is translated by the computer in a variable rate
of insulin delivery.
implantable glucose sensor with the insulin delivery device, are in progress in
several laboratories. This system is referred to as a closed-loop system, in
contrast to the former, non self-regulated system, known as the open-loop
system (Fig. 22.1). The control of insulin delivery by open-loop and closed-
loop systems, as compared to the physiological regulation of insulin secre¬
tion, is shown in Fig. 22.2.
This chapter will review the advantages of the closed-loop system of insulin
therapy, the requirements for an implantable glucose sensor, and the state of
present development and applications of glucose sensors.
22.2 Are closed-loop insulin infusion systems really necessary?
The evidence of a relationship between the microvascular complications of
diabetes mellitus and hyperglycaemia (Tchobroutsky 1978) led to the inten¬
sification of insulin therapy, either by multiple daily insulin injections or con¬
tinuous insulin infusion, in the hope that it would improve metabolic control
and therefore prevent the occurrence of these late complications. Rizza et al.
(1980) comparing the control of blood sugar by an artificial endocrine
pancreas (closed-loop system), continuous subcutaneous insulin infusion
(open-loop system), and intensified conventional insulin therapy, in insulin-
dependent diabetes, found no significant differences among the three
regimens and suggested that all three methods have the potential to achieve a
similar near-normalization of glycaemia.
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Fig. 22.2 Physiological regulation of blood glucose by the endocrine pancreas (a),
control of insulin delivery in closed-loop (b) and open-loop (c) systems. In the open-
loop system, insulin delivery is programmed to normalize the blood glucose but it is
not regulated by the glucose level.
The main advantages and disadvantages presented by these three methods
of insulin therapy are summarized in Table 22.1. Intensive conventional
insulin therapy is inexpensive, calls for no special equipment and is immedia¬
tely available to every patient. However, multiple daily injections of insulin
are necessary to achieve a near normal glycaemic control.
Open-loop devices do not have this limitation. Nevertheless, they are
expensive, must be carried by the patient, and like any mechanical devices,
are subject to malfunction. The problem of insulin aggregation, with loss of
biological activity and obstruction of the internal passages of the device has
been described (Lougheed et al. 1980). Both conventional insulin therapy and
open-loop therapy need frequent glucose measurements by the patient to
maintain adequate glycaemic control since diet and exercise demand an
adaptation of insulin doses. Both therapy methods present, however, further
advantages concerning the timing of mealtime insulin bolus and the route of
insulin delivery. The mealtime insulin bolus is not controlled by nutrient
absorption in the gut, as in normal individuals and in closed-loop therapy
(Fig. 22.2), and thus, must be controlled by the patient. As the post¬
prandial blood glucose and insulin levels are affected by the interval between
insulin administration and meal ingestion, this interval, if appropriately
chosen, may contribute to the normalization of glycaemia and insulin
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Table 22.1 Main advantages and disadvantages of different methods of
insulin therapy
Conventional
therapy Open loop Closed loop
Disadvantages Multiple injections Expensive Portable device not
available
Frequent glucose Frequent glucose Hyperinsulinaemia
measurement measurement Venous injection
Must be carried Must be carried by
by the patient the patient
Subject to Subject to
malfunction malfunction
Insulin aggregation Insulin aggregation
Advantages Immediately Immediately Independent of
available available external glucose
measurements
Inexpensive: no Free of multiple Auto-adaptation to
special equipment injections exercise and diet
changes
Subcutaneous Subcutaneous
injection injection
profile. Dimitriadis and Gerich (1983) compared the effects of 30-min sub¬
cutaneous insulin infusions started 60 min, 30 min, and immediately before
meal ingestion on postprandial plasma glucose and insulin profiles in
subjects with insulin dependent diabetes mellitus. They found that
administration of insulin 60 min before meal ingestion provided plasma
glucose and insulin profiles closest to normal and permitted less insulin to be
used. This anticipation of 60 minutes may be necessary for two complemen¬
tary reasons: first, part of this time may be required to build up a physiolo¬
gical hepatic insulinization from insulin delivered subcutaneously. Second,
insulin secretion in non-diabetic subjects is not controlled only by blood
glucose rise: the response of insulin secreting cells is anticipated under the
influence of different nerves and of gastroenteric hormones. Thus, if insulin
doses and the timing of injection or bolus infusion are carefully chosen, near
normal glucose control can be obtained by intensive conventional therapy
and open-loop systems through the subcutaneous route of insulin delivery. In
that way the complications associated with long-term vascular access for
intravenous insulin infusion can be avoided.
The main advantage of a closed-loop insulin delivery device is its indepen¬
dence of external glucose measurements and its ability to cope with the
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variations of insulin requirement brought about by exercise and diet. Never¬
theless, the glycaemic normalization achieved by these devices is frequently
associated with peripheral hyperinsulinaemia (Horwitz, Zeidler, etal. 1980).
Hyperinsulinaemia is a common feature of any insulin administration
through a peripheral route, and is mainly due to the absence of the portal-
peripheric insulin gradient. Furthermore hyperinsulinaemia might also be the
consequence of the time lag in insulin administration in response to the
glucose challenge. Thus, this hyperinsulinaemia can be avoided by the com¬
bination of the feedback controlled insulin administration with a pre-pro¬
grammed preprandial insulin infusion (Calabrese, etal. 1982). Therefore, the
possibility of a 'manual' or 'semi-automatic' mode should be considered in
the design of closed-loop systems.
Currently, closed-loop systems present several disadvantages. They are
cumbersome bedside devices that need continuous blood withdrawal from
the subject in order to ensure the automatic glucose analysis. A small
portable device is not yet commercially available. Closed-loop systems,
portable or not, need long term venous access for insulin delivery. Insulin
absorption by a subcutaneous or peritoneal route is not fast enough to enable
an efficient feedback control of the infusion rate. Finally, closed-loop
systems, being automatic devices, should be extremely reliable, both
mechanically and in the reading of the glucose sensor, otherwise their main
advantage, i.e. less demanding glucose control by the patient, would be lost.
Pump-induced insulin aggregation seems to be an additional problem to be
solved (Brennan et al. 1985).
22.3 Why is a portable closed-loop insulin infusion device
not yet available?
Such a device consists essentially of a glucose sensor, a pump and a computer
that translates the information provided by the sensor into a variable rate of
insulin infusion. The pump and the computer components of the device are
commercially available. By contrast, implantable glucose sensors that prove*
to be reliable are still to be developed.
The great majority of the glucose sensors developed so far operate through
the oxidation of /3-D-glucose by dissolved oxygen in the presence of
/3-D-glucose oxidase (GOD EC 1.1.3.4.), according to the following reaction:
^ Glucose oxidase _ . ., TT ^
Glucose + 02 ► Gluconic acid + H202
They consist of electrochemical detectors (electrodes) associated in dif¬
ferent ways with the enzyme support. The chemical reaction may be mon¬
itored via three of its constituents, i.e., oxygen depletion, gluconic acid, or
hydrogen peroxide formation.
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Table 22.2 Main requirements for a glucose sensor for an artificial beta-cell
High specificity for glucose
Linearity of response from 1 to 15 mmol/1 of glucose
Response time less than 10 minutes
Response independent of hydrodynamics and oxygen variations in tissues
Stability of glucose oxidase membrane at 37 °C in tissues
Biocompatibility
Prolonged lifetime (at least several days)
Miniaturization of the sensor head
The requirements to be fullfilled by a portable or implantable glucose
oxidase type of sensor for use in a closed-loop device (Thévenot 1982) are
described below and summarized in Table 22.2. General requirements, also
valid for other types of glucose sensors, are marked with an asterisk.
1) High specificity for glucose*. In the case of glucose oxidase sensors this
includes high enzymatic specificity and high electrochemical specificity of
associated detectors. The first condition is always valid since glucose
oxidase catalyses the oxidation of only very few species besides glucose,
and at a much lower rate (Barman 1969). On the contrary, the second
condition is often non-valid and depends mainly upon the type of electro¬
chemical detector used (see Section 22.4).
2) Linearity of in vivo response from 1 to 15 mmol/1 (Fig. 22.3b)*; this
rather limited linear range is justified by the recent findings of Harrison et
al. (1985) who described the properties of isolated human islets of
Langerhans (Fig. 22.3a). The threshold concentration of glucose required
for stimulation of insulin release was between 2 and 4 mmol/1, insulin
secretory response to glucose stimulation had half-maximal values at a
glucose concentration of approximately 5 mmol/1 and a plateau at
10 mmol/1. Under in vivo conditions the calibration curve of a glucose
oxidase sensor may not always be linear over this range (example:
Fig. 22.4, curve A). In fact, the tissue or blood glucose level, especially in
diabetics, may be higher than the apparent Michaelis constant (A"M) of
glucose oxidase solutions for glucose in air-saturated solutions, i.e. 4 to
10 mmol/1 (Apotheker A., Thévenot D.R., Wilson G.S., unpublished
data). However, it is possible to get a calibration curve linear over a much
higher concentration range, i.e. up to 20-30 mmol/1, if the glucose flux is
reduced by membranes of low permeability to glucose. This may be
achieved by an external membrane covering the enzymatic membrane
(Fig. 22.4, curve C) or by the enzymatic membrane itself (Fig. 22.4
curve B).
3) Response time less than 10 min*; Sorensen, et al. (1982) using a
theoretical physiological pharmacokinetic model of glucose homeostasis
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Fig. 22.3 (a) Insulin secretion by isolated islets in respone to glucose (after Harrison
et al. 1985). Note the sigmoidal relationship and the plateau observed at values higher
than 10 mmol/l. (b) Linearity of an implantable glucose sensor for the artificial
endocrine pancreas. Due to the response of natural beta cells, the linearity of the
sensor response may be limited to 15 mmol/l of glucose.
showed that increases in sensor delay resulted in progressive loss in glucose
regulation, exacerbation of hyperinsulinaemia, and increased insulin
requirements.
4) Independence of sensor response to fluid hydrodynamics in vessels or
tissues*.
5)Independence of sensor response to oxygen level variations in the sensor
surroundings and oxygen consumption by the sensor itself. Oxidation of
glucose by dissolved oxygen is an irreversible process with a steady state
that may be controlled either by the enzymatic oxidation reaction with
high temperature dependence (6-10%/°C) or by substrate diffusion with
low temperature dependence (2-4°7o/°C) (Racine and Mindt 1971; Kamin
and Wilson 1980). Under such heterogeneous kinetics, the glucose
electrode consumes what it is supposed to monitor. This is a characteristic
common to Clark's oxygen sensor (see Section 22.4.1.). Whatever the
electrochemical detector associated with the glucose oxidase membrane,
the stability of its readings is affected by external diffusion (i.e. fluid flow
rate near the membrane), internal diffusion (i.e. permeability to sub¬
strates), as well as by oxygen concentration level in or near the mem-
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Fig. 22.4 Different types of calibration curves for a glucose sensor using different
glucose oxidase membranes (after Sternberg R., Tallagrand T., Thévenot D. R..
Unpublished data): (a) GOD collagen membrane (right-side Y axis), (b) GOD
cellulose acetate membrane (left-side Y axis), (c) GOD collagen membrane covered
with a pinholed Teflon membrane (left-side Yaxis). Note that the use of an additional
non-enzymatic membrane or of a cellulose acetate membrane both extends the linear
range of the system and impairs its sensitivity.
branes. In an ideal situation these factors should be kept constant. In the
case of implantable glucose electrodes these ideal conditions are difficult
to obtain. Clark's oxygen detectors that have a cathode diameter
approximately equal to the membrane thickness (10-20 microns), are less
dependent on hydrodynamics, due to the hemispheric diffusion pattern (in
contrast with the linear pattern) obtained under this particular situation
(Bard and Faulkner 1980; Wightman 1981). Accessibility of substrates
and adequate oxygen level at enzymatic sites can be indirectly controlled
by using an additional external membrane more permeable to oxygen than
to glucose and/or by using enzymatic layers with a high partition
coefficient for oxygen.
6) Long-term mechanical, chemical, and enzymatic stability of glucose
oxidase and its support at 37°C, in whole blood, lymph, or tissue.
7) No leaking of glucose oxidase into fluids and tissues surrounding the
sensor; being a foreign enzyme, its recognition by the immune system
would provoke an immune reaction.
8) Biocompatibility of all implanted parts of the sensor; absence of
implant encapsulation by fibroblasts and giant cells*. Woodward (1982)
suggested that the optimal configuration for a subcutaneously
implantable sensor is in the form of a wire or filament. Such a structure, if
measuring less than about 2 mm in diameter, would evoke a minimal
tissue response.
20- r 600
0 5 10 15 20
Glucose (mmoi/I)
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9) The scaling down of the sensor should not modify the geometrical,
physical, and enzymatic characteristics which control its analytical
properties.
10) The system should require minimal calibration and zero adjustment*.
11) Finally, the sensor should have a prolonged lifetime, it should be
easily replaceable if necessary and not be expensive if it has to be
replaced*. In the case of sensors to be partially inserted in the sub¬
cutaneous tissue, in a needle-like fashion, a lifetime of several days, if not
weeks, could be accepted. Obviously, a totally implantable device would
require a much longer lifetime.
In the remaining sections of this chapter an overview is presented of the
significant results obtained in the development of glucose sensors and their
application in closed-loop insulin infusion devices.
22.4 Glucose oxidase electrochemical sensors for the artificial endocrine
pancreas: types of detectors.
22.4.1 Oxygen detectors
Clark and Lyons ( 1962) described the first specific glucose electrode (Chapter
1). The enzyme was retained on a polymer membrane and an amperometric
oxygen electrode estimated the decrease of oxygen as the reaction proceeded.
The Clark-type oxygen electrodes are almost insensitive to all types of
interfering substances, but they are obviously very sensitive to variations in
partial pressure of oxygen within the fluid in contact with the electrode.
Thus, misreadings due to physiological or pathological fluctuations of
oxygen partial pressure are to be expected under in vivo conditions. This
problem may be surmounted by the addition of a second electrode, not
associated with a glucose oxidase membrane, forming a differential system
(Updike and Hicks 1967).
Improvements in this system by Bessmann and Schultz (1973) led to a
prototype implantable sensor using two galvanic oxygen electrodes as
detector. Oxygen had access to the electrodes through a polypropylene mem-
brane, the external side of which was fastened to a matrix of nylon cloth.
Glucose oxidase was covalently bound to the matrix, in the working
electrode, by glutaraldehyde. The whole was contained in a plastic disc of
2 cm diameter by 0.25 cm depth. The sensor had a useful in vivo lifetime of
four days but a less than optimal sensitivity to glucose, due in part to the low
oxygen partial pressure in subcutaneous tissues (Bessman et al. 1977).
An additional problem with this type of sensor (Fig. 22.5a) is the com¬
petition for oxygen between the glucose oxidase membrane (flux v2) and the
oxygen detector itself (flux v,); if the cathode is not small enough, the latter
flux may interfere with the apparent glucose oxidase activity.
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Fig. 22.5 Types of detectors used in glucose oxidase electrochemical sensors for
artificial endocrine pancreas: (a) oxygen cathodic; (b) hydrogen peroxide anodic;
and (c) cofactor detector. See text for explanation.
22.4.2 pH detectors
9
Glucose sensors based on the detection of gluconic acid via a pH electrode
have been developed. Nevertheless they present poor sensitivity, selectivity,
and linearity of calibration curves (Nilson et al. 1973) and thus cannot be
implanted in the highly buffered body fluids.
22.4.3 Hydrogen peroxide amperometric detectors
Amperometric detection of enzymatically generated hydrogen peroxide is
probably the most developed type of glucose sensor (Guilbaut and Lubrano
1973; Scheller et al. 1977; Thévenot et al. 1978) (Fig. 22.5b). Clemens et al.
(1977) adapted one of such sensors for use in a bedside-type artificial
pancreas. Similar sensors have been adapted for the same purpose by several
groups (see Section 22.7). Over the last ten years, improvements have been
made in the sensor design, the binding of the enzyme to its support, and the
functional characteristics of the electrodes.
This type of detector is very sensitive to glucose; its lowest detection limit
may reach 10 nmol/1 (Thévenot et al. 1978). Hydrogen peroxide ampero¬
metric detection is also very sensitive to naturally occurring electron donors,
such as ascorbate, urate, and tyrosine. Methods have been developed
to increase the selectivity of the glucose electrode towards such interfering
substances. Either the response is compensated by a non-enzymatic detector
(Thévenot et al. 1978) or the platinum anode is covered by selectively
impermeable membranes (cellulose acetate, for instance) with pores that will
exclude ascorbate and most other potential interfering substances (Yellow
Springs Instrument Co. 1975).
The independence on oxygen concentration of hydrogen peroxide detec¬
tion is an advantage in sensor design. Nevertheless the local oxygen level
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necessary for the enzymatic reaction to occur must be taken into account: in
that way, membrane partition and diffusion coefficient for oxygen play an
important role in glucose response patterns. Oxygen is regenerated during the
electrochemical oxidation of hydrogen peroxide on the platinum surface
according to the reaction:
H202 > 02 + 2H* + 2e-
Optimization of the collection efficiency of the detector (Fig. 22.5b) i.e., the
ratio between the part of the enzymatically generated hydrogen peroxide flux
oxidized on the platinum (v,) and the total flux (v, + v2), v2 being the part of
the flux diffusing towards the bulk solution, would result in a greater avail¬
ability of oxygen in the enzymatic layer and in a greater independence of
oxygen diffusion from the bathing fluids, once the reaction had started
(Coulet etal. 1980).
Finally, hydrogen peroxide anodic oxidation is not always diffusion con¬
trolled and its rate may limit the signal from the sensor. This rate may depend
on electrode conditioning (Dubois 1984).
22.4.4 Hydrogen peroxide potentiometric detection
Potentiometric measurement of glucose concentration is the principle of a
sensor developed by Schiller, Wingard, and Liu (1982; Chapter 10). Glucose
oxidase is immobilized directly on the platinum surface of the working
electrode by methods including entrapment in polyacrylamide gel, cross-
linking in an albumin matrix with glutaraldehyde, and coupling to platinum
through gamma-aminopropyltriethoxy silane (Wingard et al. 1979).
In contrast to amperometric detections in which an external potential is
applied between the electrodes, and in which oxygen or hydrogen peroxide
local concentrations are directly monitored through the generated current,
potentiometric detection measures a pseudo-equilibrium potential inside the
system. The electrochemcial reaction responsible for this potential appears to
result from the interactions between the enzymatically generated hydrogen
peroxide and the platinum surface (Wingard et al. 1982). The electrode
cleaning procedure is always critical to the functioning of the system.
Linearity of response, as the logarithm of glucose concentration, was
achieved in in vitro studies over the range of about 0.6 to 22 mmol/1.
Theoretical advantages of this system for in vivo utilization, due to the low
potential generated, include minimal electrochemical interference and the
possibility of micro-miniaturization of the electrode.
22.4.5 Cofactor detectors
The concept of cofactor detectors is based on the ability of cofactors to act as
temporary acceptors of the protons and electrons released during the oxida¬
tion of substrates by oxidation-reduction enzymes (Chapter 15). The general
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idea is to have a solid state type electrode in which a naturally-occurring or an
artificial cofactor is an integral part of the electron conducting support and
the enzyme is immobilized with the cofactor. The electrode, as a whole,
behaves as a cofactor, i.e. an electron acceptor or donor for an enzymatic
reaction (Fig. 22.5c).
The coupling of riboflavin to solid carbon, forming a solid state pathway
for easy electron transfer, has been described (Wingard 1982). Subsequent
developments (Wingard 1983tf) included the conversion of immobilized
riboflavin to FAD and the appearence of enzymatic activity on the addition
of the apoenzyme of glucose oxidase. Later, Cass et al. (1984) used entrapped
ferrocene derivatives, as ferricinium ions, which may be electrochemically
oxidized and react with reduced glucose oxidase. If such reagents are
present in sufficient excess, then the supply of oxygen to the catalytic
layer would have little effect on the enzymatic rate (see Chapters 15 and 16).
Recently, Ikeda et al. (1985) described a glucose sensor using benzoquinone
as a cofactor. Glucose oxidase was immobilized on the surface of a p-
benzoquinone-carbon paste electrode by coating the enzyme-loaded surface
with a nitrocellulose film. Properties of the sensor include the electrocatalytic
oxidation of glucose with a linear range up to 15 mmol/1, the response time
of about 20 seconds and the insensitivity to variations of oxygen tension in
sample solutions.
22.5 Designs of in vivo glucose oxidase sensors
The latest developments towards an implantable glucose sensor have
favoured three types of sensor design: the plane-geometry type, the vessel-
shaped, and the needle type. Plane geometry sensors consist basically of a
plane surface support containing the metal working electrode and the
reference and counter electrodes coated by various combinations of
enzymatic and non-enzymatic, hydrophilic and hydrophobic membranes.
The membranes provide a support for the enzyme, an environment for the
chemical reaction, and a diffusion barrier assuring the optimal concentra¬
tions of glucose and oxygen in this environment. Fischer and Abel (1982)
described a plane-geometry sensor mounted into a flow chamber. It consisted
of a platinum anode for the measurement of hydrogen peroxide, a
silver/silver chloride reference and counter electrode, glucose oxidase
immobilized onto sepharose and held by hydrophilic cellulose acetate mem¬
branes, and an hydrophobic perforated Teflon membrane in front of the
anode. In vivo tests using normal and diabetic dogs showed reasonable
correlation between the sensor output and the plasma glucose reference
values with a response time between 90 and 120 seconds. The linear range for
in vitro calibration was up to 40 mmol/1 of glucose.
An original approach was described by Kondo et al. (1981): the sensor is a
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vessel-shaped device through which the blood Hows. Oxygen-type electrodes
and membranes are disposed around its wall. The sensor is introduced into
the circulatory system in a fashion similar to an external arterio-venous shunt
for hemodialysis. The linear range is up to 16 mmol/l of glucose and the
response time is about 10 minutes.
The needle-type sensors are usually micro-electrodes having a platinum
core (anode) isolated from an external silver/silver chloride cathode
reference and counter-electrode. The electrode is coated with glucose oxidase
immobilized in a solution of a matrix material (cellulose diacetate, for
instance) in a volatile solvent (acetone, for instance). Shichiri, et al. (1982;
Chapter 23) have described a subcutaneously implantable needle-type sensor
having an in vivo response time of 2 to 5 min and a linear response of up to
27 mmol/l of glucose (see Section 22.7).
22.6 Glucose sensors: possible alternative approaches
Glucose sensors based on non-enzymatic approaches have been known for
many years. Although they purport to avoid the difficulties associated with
heterogeneous enzyme kinetics none of these systems is presently sufficiently
developed to permit in vivo implantation.
The characteristics of direct electrochemical sensors, consisting of
platinum electrodes not associated with glucose oxidase have been studied
(Soeldner et al. 1973; Gebhardt et al. 1978; Richter, et al. 1982). The signal is
generated by direct glucose oxidation at the anodic surface of a platinum
electrode, in response to alternate anodic and cathodic potentials. Their
specificity to glucose, in biological fluids, is still less than optimal, due to the
interference of endogenous oxidizable substances such as amino acids, urea,
ascorbic acid, and of exogenous substances such as alcohol and several drugs.
The selection of adequate working potentials and the use of an external
selective membrane brings real improvement to the system specificity. An
additional problem with this type of detector is the poisoning of the platinum
surface by adsorption of gluconic acid and amino acids, which leads to the
gradual deactivation of the anode catalyst and inhibition of further oxida¬
tion. The deactivation can be offset with regeneration of the working
electrode by repeated surface oxidation by electrochemical pulsing.
Nevertheless, oxidized radicals are generated and desorbed from the
electrode surface together with products of electrode degradation. The
present status of the electrocatalytic glucose sensor does not favour its use as
an implantable device.
The competition of glucose and fluoresceine-labelled polydextran for the
binding sites of the protein concanavalin A, immobilized on the inside sur¬
face of a hollow dialysis fibre, is the principle of a sensor developed by
Schultz, et al. (1982; Chapter 32). This affinity sensor is completed by an
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optical fibre inserted in the lumen of the dialysis fibre that allows the
measuring of the unbound labelled dextran. This approach presents an
advantage, compared to glucose oxidase sensors: the response is determined
by the competitive equilibrium between glucose and the signal producing
ligand. Thus, kinetics of enzyme reactions and electrode fouling do not affect
the magnitude of the sensor response. Optimal specificity and sensitivity
could be obtained by the selection of appropriate binding protein and com-*
petitive ligand; specific antibodies could be used, for instance. The sensor
still suffers from limited stability and relatively long response times when
employed as an in vivo sensor.
The concept of non-invasive glucose monitoring of the aqueous humor of
the eye, by the measurement of the degree of optical rotation produced by the
local concentration of glucose, has been advanced by March et al. ( 1979). The
requirement of heavy optical equipment is an important drawback in terms
of its development into a portable device.
Several endogenous enzymes that use glucose as the primary substrate
might be utilized in an enzymatic glucose sensor. They include glucose
dehydrogenase, glucokinase, glucose-6-phosphatase and glucose-isomerase
(Wingard 19836). In the case of glucose dehydrogenase NAD+ /NADH con¬
centrations could be monitored using a miniature fibre optic spectrometer.
At the present time this system is still a theoretical speculation.
The last part of this chapter will deal will the glucose sensor as a part of a
closed-loop insulin infusion system. The main characteristics of some
implantable sensors are described in Table 22.3.
Table 22.3 Main characteristics of some implantable glucose sensors
Authors
Bessman Fischer Kondo Shichiri
Type of detector Galvanic cell Pt anode/
u n
02 (Clark) Pt anode/H20
Enzymatic Nylon
H2U2
Sepharose Nylon Cellulose
membrane material acetate
Immobilization Covalently Covalently Covalently Covalently
procedure bound by bound by bound by bound by
glutaraldehyde cyanogen glutaraldehyde glutaraldehyde
bromide
Non-ezymatic (1) Polypropylene Cellulose Polypropylene Polyurethane
membrane material acetate
Non-enzymatic (2) Perforated Perforated Polyvinyl-
membrane material Teflon Teflon alcohol
Sensor geometry Plane Plane Vessel- Needle-
geometry geometry shaped shaped
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22.7 The artificial beta cell
The earliest external electromechanical device used as a closed-loop insulin
infusion system was described by Kadish (1964). Whenever the blood glucose
exceeded 1.5 g/1 (8.33 mmol/1) or fell under 0.5 g/1 (2.77 mmol/1), insulin
or glucagon, respectively, were infused. However this on-off system was not
able to normalize the glycaemia. A resurgence of interest in the seventies for
this bedside instrument, which became known as artificial beta-cell, led to the
refining of the feed-back controlled systems commanding the insulin
delivery. Kadish's device was improved by Albisser et al. (1974) who
subjected the control of insulin delivery to a computer calculated predicted
value based on the minute-to-minute variations of blood sugar. Clemens et
al. (1977) constructed the first of these devices to be commercially available.
It was named Biostator Glucose-Controlled Insulin Infusion System (60 kg,
42 x 46 x 46 cm). A number of similar artificial beta cells, using extra¬
corporeal glucose sensors, have been since then fabricated and evaluated by
several groups, including Mirouze et al. (1977), Slama et al. (1977), Kraegen
et al. (1979), Goriya, et al. (1979) and Fischer, et al. (1980).
Bessman et al. (1977) reported the implantation into a diabetic dog of a
small artificial beta cell consisting of an oxygen-detector glucose sensor,
electronics, a micro pump, and a power supply. The sensor was similar to the
one previously described in Section 22.4.1. The pump was a piezoelectric
device separated from the insulin reservoir by a solenoid valve. Insulin was
delivered into the peritoneal cavity when appropriately phased pulses were
applied to the pump and valve. However, in this experiment, as well as in the
observations on seven additional dogs (Bessman et al. 1981), the amount of
insulin administered to the dogs was clearly insufficient, due to the
inadequate response of the glucose sensor to the glucose levels.
A remarkable achievement in terms of miniaturization was reported by
Shichiri et al. (1982) who developed a wearable closed-loop device (400 g,
12 x 15 x6 cm) associated with an implantable needle-type sensor. Short
term glycaemic control was achieved in diabetic patients connected to the
instrument (Shichiri et al. 1984). These results are presented in Chapter 23 of
this book.
22.8 Conclusion
Our understanding of the physiological, physicochemical, and electro¬
chemical mechanisms underlying the basic requirements for an in vivo
glucose sensor has expanded in recent years. The fruits of this understanding,
in terms of technology, are beginning to be available. However, several ques¬
tions remain unanswered and several answers are still not translated into
practice.
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Concerning the sensor functioning under conditions of in vivo implanta¬
tion, the optimal arrangement of the glucose oxidase support and the
protective membranes has still to be found, allowing long term enzymatic
stability and adequate glucose and oxygen local concentrations with minimal
tissue reaction. A better understanding of the operational properties of
such sensors, both in vitro and in vivo, would allow their design and
performance to be optimized.
Other approaches than the glucose oxidase sensor may prove to be worth¬
while. The affinity type of sensor could be a promising alternative. Implant¬
able sensors usually require a membrane barrier between the sensing element
and the biological fluid. It is clear that the failure of such membranes to
maintain reproducible analyte transport characteristics is a major cause of
biosensor malfunction.
Finally, the expectations aroused by the development of a reliable sensor
for long term use in a portable closed-loop insulin infusion system justify the
efforts being made in ongoing studies. More easily attainable good glycaemic
control in diabetic subjects could, hopefully, prove to be a major step in the
prevention of the late complications of diabetes.
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